MoonLake Immunotherapeutics (MLTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.05: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 5.80; Below-average business quality.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in... Read more
Sell if holding. Engine safety override at $18.05: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 5.80; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — MoonLake Immunotherapeutics
Latest news
- NEWS BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target — benzinga Jun 9, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target — benzinga Jun 8, 2026 positive
- NEWS Moonlake Immunotherapeutics Inks Master Commercial Supply Agreement With Vetter Pharma To Manufacture One Or More Applic — benzinga Jun 1, 2026 positive
- NEWS Needham Maintains Buy on MoonLake, Raises Price Target to $30 — benzinga May 12, 2026 positive
- NEWS FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars — benzinga May 11, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.05: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 5.80; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.74. Score 4.7/10, moderate confidence.
Take-profit target: $24.03 (+33.5% upside). Prior stop was $16.74. Stop-loss: $16.74.
Quality below floor (1.5 < 4.0).
MoonLake Immunotherapeutics trades at a P/E of N/A (forward -5.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover MLTX with a consensus score of 4.0/5. Average price target: $28.
What does MoonLake Immunotherapeutics do?MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory...
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.